Alzamend Neuro, Inc.
ALZN · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | $9 | $5 | $5 | $57 |
| - Cash | $4 | $6 | $4 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | -$1 | $1 | $53 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$3 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$3 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -1.28 | -2.22 | -0.19 |
| % Growth | 76.6% | 42.3% | -1,068.4% | – |
| Operating Cash Flow | -$1 | -$2 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$1 | -$2 | -$1 | -$1 |